Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724922 | SCV000332429 | uncertain significance | not provided | 2015-06-30 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000724922 | SCV000582121 | uncertain significance | not provided | 2024-04-24 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV001859550 | SCV002162168 | uncertain significance | Ehlers-Danlos syndrome, musculocontractural type | 2022-03-25 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 48 of the CHST14 protein (p.Ala48Val). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with CHST14-related conditions. ClinVar contains an entry for this variant (Variation ID: 281584). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002392794 | SCV002702892 | uncertain significance | Cardiovascular phenotype | 2022-12-14 | criteria provided, single submitter | clinical testing | The p.A48V variant (also known as c.143C>T), located in coding exon 1 of the CHST14 gene, results from a C to T substitution at nucleotide position 143. The alanine at codon 48 is replaced by valine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |